![](/img/cover-not-exists.png)
First-in-human, phase I/IIa clinical study of the peptidase potentiated alkylator melflufen administered every three weeks to patients with advanced solid tumor malignancies
Berglund, Åke, Ullén, Anders, Lisyanskaya, Alla, Orlov, Sergey, Hagberg, Hans, Tholander, Bengt, Lewensohn, Rolf, Nygren, Peter, Spira, Jack, Harmenberg, Johan, Jerling, Markus, Alvfors, Carina, RingbVolume:
33
Language:
english
Journal:
Investigational New Drugs
DOI:
10.1007/s10637-015-0299-2
Date:
December, 2015
File:
PDF, 435 KB
english, 2015